Resources Repository
-
EditorialPublication 2019Quality Transparency in Health Care
The immediate promise of using public reporting to increase quality transparency is that it will …
The immediate promise of using public reporting to increase quality transparency is that it will enable consumers to choose the providers best suited to their needs and thereby lead to improved patient outcomes and welfare. Unfortunately, however, early empirical findings failed to detect such anticipated benefits from public reporting. For example, studies have indicated that the launch of the Hospital Compare website and other efforts aimed at increasing quality transparency have not resulted in improved…
Policy/Regulation | Health/Medicine | North America -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Policy/Regulation | Decision Theory | Costing Methods | Health Outcomes | State-Transition | Decision Analysis | Infectious Diseases | Economics/Finance | Government/Law | Health/Medicine | Middle East & North Africa -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Policy/Regulation | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Policy/Regulation | Value of Information | State-Transition | Benefit-Cost Analysis | Infectious Diseases | Economics/Finance | North America | Europe -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Social Determinants | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Culture/Society | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2019Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
This analysis estimates state-specific and demographic subgroup-specific trends and projections of the prevalence of categories …
This analysis estimates state-specific and demographic subgroup-specific trends and projections of the prevalence of categories of body-mass index (BMI) in the United States. Self-reported BMI from the Behavioral Risk Factor Surveillance System Survey (1993-1994 and 1999-2016) were obtained and corrected for quantile-specific self-reporting bias. Multinomial regressions were then fitted for each state and subgroup to estimate the prevalence of four BMI categories from 1990 through 2030: underweight or normal weight (BMI <25), overweight (25 to…
Social Determinants | Health Outcomes | Mathematical Models | Calibration/Validation | Chronic Disease/Risk | North America -
ArticlePublication 2022Excess Mortality and Elevated Body Weight in the U.S.
This analysis estimates excess mortality associated with elevated body weight in the United States by …
This analysis estimates excess mortality associated with elevated body weight in the United States by state and demographic subgroup. The authors developed a nationally-representative microsimulation (individual-level) model of US adults between 1999 and 2016, based on risk factor data from the Behavioral Risk Factor Surveillance System and body-mass index (BMI) mortality hazard ratios from a global pooling dataset. The model was calibrated to empirical all-cause mortality rates from CDC WONDER by state and subgroup, and…
Social Determinants | Health Outcomes | Microsimulation | Calibration/Validation | Chronic Disease/Risk | North America -
ArticlePublication 2022Distributional Effects of Tobacco Tax Increases across Mexico: An ECEA
This study examines the distributional impacts of a one-peso tobacco tax increase in Mexico, focusing …
This study examines the distributional impacts of a one-peso tobacco tax increase in Mexico, focusing on health, poverty, and financial outcomes at the subnational level. Utilizing an extended cost-effectiveness analysis, the research estimates various metrics such as life-years gained, smoking attributable deaths averted, treatment costs averted, and financial impacts by income group across five regions. Findings reveal that the tax increase would lead to significant benefits, including approximately 1.5 million smokers quitting across the regions,…
Policy/Regulation | Cost-Effectiveness Analysis | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2022Potential Distributional Health & Financial Benefits of Increased Tobacco Taxes in Ethiopia: Findings from a Modeling Study
This study evaluates the potential impacts of Ethiopia's tobacco tax increase in 2020, which raised …
This study evaluates the potential impacts of Ethiopia's tobacco tax increase in 2020, which raised cigarette prices by approximately 67%. Employing parameters such as price elasticity of demand and smoking prevalence, the analysis utilizes existing literature and secondary data to model the effects of the reform on various outcomes, focusing on life years, tax revenues, cigarette expenditures, and catastrophic health expenditures (CHE). Concentrating solely on male smokers due to low female smoking rates, the results…
Policy/Regulation | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa